ArticleJournal of cachexia, sarcopenia and muscle2026
Vitamin D Ameliorates Skeletal Muscle Atrophy After Spinal Cord Injury by Upregulating TIGAR and Enhancing Mitochondrial Function.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSkeletal muscle atrophy following spinal cord injury (SCI) is a debilitating secondary complication with no effective treatment. This study aimed to investigate the therapeutic efficacy of vitamin D (VD) in SCI-induced muscle atrophy and to elucidate the underlying molecular mechanisms.
methodsSCI patients' serum VD levels were measured, and muscle mass was assessed using dual-energy X-ray examination. Adult male C57BL/6 mice underwent a complete T10 spinal cord transection or sham surgery. On Day 3 post-injury, mice received daily oral gavage of either VD (150 IU/kg) or vehicle (coconut oil) for 25 days. Body weight and motor function were assessed, and muscle-specific parameters including hindlimb circumference, muscle mass, fibre cross-sectional area (CSA) and fibre type composition were evaluated. Quantitative proteomics, Western blotting, and transmission electron microscopy (TEM) were further employed to investigate the molecular mechanisms in the gastrocnemius muscle.
resultsSerum VD level showed a significant positive correlation with the muscle index (R
conclusionVD mitigates skeletal muscle atrophy following SCI by restoring metabolic and mitochondrial homeostasis through the upregulation of TIGAR. Our findings establish a strong preclinical rationale for investigating VD supplementation as a therapeutic strategy to preserve muscle health in SCI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.